GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...
GSK says asthma and nasal polyps therapy under EU review
GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, ...
Pharmaceutical Technology14h
GSK and University of Oxford partner for cancer vaccine research
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.
EuropaWire1d
GSK and University of Oxford Launch Cancer Prevention Research Program with £50 Million Investment
GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...
GSK, Oxford to establish GSK-Oxford Cancer Immuno-Prevention Programme
GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...
consalud.es6d
La CE aprueba el uso de dostarlimab con quimioterapia a todas las adultas con cáncer de endometrio
Esta ampliación de dostarlimab, de GSK, incluye los tumores MMRp/MSS, que representan aproximadamente el 75% de los casos de ...
Info Salus6d
La Comisión Europea aprueba 'JEMPERLI' en combinación con quimioterapia estándar para cáncer de endometrio
La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar ...